Agenus to Present at OneMedForum San Francisco 2013
* Reuters is not responsible for the content in this press release.
http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130102:nGNXUWWWKa LEXINGTON, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a developer of therapeutic vaccines for cancer and infectious diseases, today announced that the company will be presenting at the 6th Annual OneMedForum San Francisco 2013, which will be held at the Sir Francis Drake Hotel in San Francisco. Dr. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Tuesday, January 8th at 9:40 am PST in the Franciscan Room. Between Agenus and its partners, 19 programs are in clinical development. Agenus' QS-21 Stimulon® adjuvant1 is being studied in clinical trials for 17 vaccine indications. They include: * Phase 3: GSK's RTS,S for malaria2 * Phase 3: GSK's MAGE-A3 for non-small cell lung cancer2 * Phase 3: GSK's MAGE-A3 for melanoma2 * Phase 3: GSK's Zoster Herpes for shingles2 * Phase 2: Janssen's ACC-001 for Alzheimer's disease Agenus pipeline programs include: * Phase 2: Prophage Series G-100 for newly diagnosed glioma * Phase 2: Prophage Series G-200 for recurrent glioma * Phase 2 : HerpV (contains QS-21 Stimulon) for genital herpes Saponin Platform: QS-21 Stimulon ® Adjuvant Agenus' licensees include GlaxoSmithKline and Janssen Alzheimer Immunotherapy. Agenus is generally entitled to receive milestone payments as QS-21-containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions. Heat Shock Protein Platform: Prophage Series G The Prophage Series G vaccines (HSPPC-96; vitespen) are being studied in two different settings of glioma: newly diagnosed and recurrent disease. Glioma is the deadliest form of brain cancer with an average survival of six to 14 months. Heat Shock Protein Platform: Recombinant Series HerpV HerpV is the most advanced HSV-2 vaccine currently in clinical development for the treatment of genital herpes. A Phase 2 study measuring the effect of vaccination on viral shedding in individuals infected with HSV-2 is underway. Data results for this study are anticipated in Q4'13. Experts in HSV-2 clinical research believe that a reduction in viral shedding could translate into the clinical benefit of a reduction in recurrent outbreaks. Web Cast Information The live and archived webcast of the company presentation will be accessible from the company's website at www.agenusbio.com/webcast http://www.globenewswire.com/newsroom/ctr?d=10016901&l=12&a=www.agenusbio.com%2Fwebcast&u=http%3A%2F%2Fwww.agenusbio.com%2Fwebcast . Please log in approximately 5-10 minutes before each event to ensure a timely connection. The archived replay will be available on the Agenus website for one month following the conference. About Agenus Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, please visit www.agenusbio.com http://www.globenewswire.com/newsroom/ctr?d=10016901&l=14&a=www.agenusbio.com&u=http%3A%2F%2Fwww.agenusbio.com%2F . The Agenus logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8187 http://www.globenewswire.com/newsroom/ctr?d=10016901&l=15&u=http%3A%2F%2Fwww.globenewswire.com%2Fnewsroom%2Fprs%2F%3Fpkgid%3D8187 Forward-Looking Statement This press release contains forward-looking statements, including statements regarding up-coming presentations and technologies, programs, and activities of the company and its licensees. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended September 30, 2012. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus' business and securities, investors should give careful consideration to these risks and uncertainties. 1. QS-21 Stimulon adjuvant and the related agreements, and HerpV are assets of Antigenics Inc., a wholly owned subsidiary of Agenus Inc. 2. QS-21 is a component of GSK adjuvant systems. Stimulon is a registered trademark of Agenus Inc. and its subsidiaries. CONTACT: Media and Investor Contact: Jonae R. Barnes Vice President Investor Relations and Corporate Communications firstname.lastname@example.org 617-818-2985
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- Secret Service investigates after man jumps White House fence, reaches doors
- French jets strike in Iraq, expanding U.S.-led campaign against Islamic State |
- Scots spurn independence in historic vote, devolution battle begins |
- Thousands of Syrian Kurds flee to Turkey as Islamic State advances |